Gilead Sciences Sustainability Profile
Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.
DitchCarbon Score
How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gilead Sciences's score of 58 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Gilead Sciences's reported carbon emissions
In 2023, Gilead Sciences, headquartered in the US, reported total carbon emissions of approximately 1,200,233,000 kg CO2e. This includes Scope 1 emissions of about 56,096,000 kg CO2e, Scope 2 emissions of approximately 22,339,000 kg CO2e, and significant Scope 3 emissions totalling around 1,121,798,000 kg CO2e. Gilead has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 46% by 2030, using a 2019 baseline. Additionally, the company has committed to a 15% reduction in absolute Scope 3 emissions over the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit warming to 1.5°C. Furthermore, Gilead aims to achieve carbon net-zero operational GHG emissions by 2030, reinforcing its commitment to sustainability and environmental responsibility. The company’s strategy includes a near-term goal of reducing Scope 1 and 2 emissions by 25% by 2025 compared to a 2016 baseline. Overall, Gilead Sciences is actively working towards significant reductions in its carbon footprint, demonstrating a strong commitment to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 44,754,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 36,813,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Gilead Sciences's Industry?
How Carbon Intensive is Gilead Sciences's Location?
Gilead Sciences's Scope 3 Categories Breakdown
Gilead Sciences's Scope 3 emissions, which decreased by 7% last year and increased by approximately 3% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Top Scope 3 Categories
Gilead Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Gilead Sciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Gilead Sciences's sustainability data and climate commitments